These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7571222)

  • 1. An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.
    Oesterling JE; Moyad MA; Wright GL; Beck GR
    Urology; 1995 Oct; 46(4):524-32. PubMed ID: 7571222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR; Ou YC; Horng YY; Lee HS
    Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.
    Jacobsen SJ; Klee GG; Lilja H; Wright GL; Oesterling JE
    Urology; 1995 Mar; 45(3):447-53. PubMed ID: 7533456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.
    Prestigiacomo AF; Stamey TA
    J Urol; 1996 Jun; 155(6):1977-80. PubMed ID: 8618301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)--multi-centre study results. The PSA Study Group.
    Schambeck CM
    Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):541-7. PubMed ID: 8547440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
    Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
    Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability analysis of first and second generation PSA assays.
    Wymenga LF; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
    Can J Urol; 2000 Aug; 7(4):1070-6. PubMed ID: 11109077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of Tandem-R PSA and Markit-M PA in the diagnosis of prostate cancer].
    Okegawa T; Kato M; Miyata A; Murata A; Miura I; Yoneda T; Nutahara K; Higashihara E
    Hinyokika Kiyo; 1999 Mar; 45(3):175-8. PubMed ID: 10331169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
    Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
    Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 3 investigational assays for the free form of prostate specific antigen.
    Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
    J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen.
    Jacobsen SJ; Lilja H; Klee GG; Wright GL; Pettersson K; Oesterling JE
    Urology; 1994 Oct; 44(4):512-8. PubMed ID: 7524236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in measurement of prostate-specific antigen: importance of method and lot variability.
    Wener MH; Daum PR; Brawer MK
    Clin Chem; 1995 Dec; 41(12 Pt 1):1730-7. PubMed ID: 7497613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen.
    Nixon RG; Lilly JD; Liedtke RJ; Batjer JD
    Arch Pathol Lab Med; 1997 Apr; 121(4):385-91. PubMed ID: 9140308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of three free and total PSA assays.
    Roth HJ; Stewart SC; Brawer MK
    Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):326-331. PubMed ID: 12496875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production, analysis, and characterization of reference materials for prostate-specific antigen.
    Garg UC; Howanitz JH; Nakamura RM; Plous RH; Eckfeldt JH
    Arch Pathol Lab Med; 1995 Dec; 119(12):1104-8. PubMed ID: 7503657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay.
    Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK
    Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay.
    Klee GG; Dodge LA; Zincke H; Oesterling JE
    J Urol; 1994 Jan; 151(1):94-8. PubMed ID: 7504749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.
    van Iersel MP; Thomas CM; Segers MF; Witjes WP; Debruyne FM; Oosterhof GO
    Br J Urol; 1996 Mar; 77(3):418-22. PubMed ID: 8814849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.